PT3055333T - Use of a pcsk9 inhibitor to treat hyperlipidemia - Google Patents

Use of a pcsk9 inhibitor to treat hyperlipidemia

Info

Publication number
PT3055333T
PT3055333T PT148025273T PT14802527T PT3055333T PT 3055333 T PT3055333 T PT 3055333T PT 148025273 T PT148025273 T PT 148025273T PT 14802527 T PT14802527 T PT 14802527T PT 3055333 T PT3055333 T PT 3055333T
Authority
PT
Portugal
Prior art keywords
pcsk9 inhibitor
treat hyperlipidemia
hyperlipidemia
treat
pcsk9
Prior art date
Application number
PT148025273T
Other languages
Portuguese (pt)
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of PT3055333T publication Critical patent/PT3055333T/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT148025273T 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia PT3055333T (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361890154P 2013-10-11 2013-10-11
US201461923103P 2014-01-02 2014-01-02
US201461955514P 2014-03-19 2014-03-19
US201462004620P 2014-05-29 2014-05-29
US201462025104P 2014-07-16 2014-07-16
EP14306221 2014-07-31
US201462054571P 2014-09-24 2014-09-24
EP14306584 2014-10-09

Publications (1)

Publication Number Publication Date
PT3055333T true PT3055333T (en) 2020-03-11

Family

ID=68918439

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148025273T PT3055333T (en) 2013-10-11 2014-10-10 Use of a pcsk9 inhibitor to treat hyperlipidemia

Country Status (4)

Country Link
ES (1) ES2779126T3 (en)
IL (1) IL271456B (en)
PT (1) PT3055333T (en)
TW (1) TWI723478B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114525258A (en) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 Pluripotent stem cell expressing PCSK9 blocker or derivative thereof and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
SG192117A1 (en) * 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
JOP20200043A1 (en) * 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders

Also Published As

Publication number Publication date
TWI723478B (en) 2021-04-01
IL271456B (en) 2021-08-31
ES2779126T3 (en) 2020-08-13
IL271456A (en) 2020-01-30
TW202021615A (en) 2020-06-16

Similar Documents

Publication Publication Date Title
IL244995A0 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
IL279682A (en) Benzoquinolone inhibitors of vmat2
LT3080100T (en) Inhibitors of lysine specific demethylase-1
EP2948450A4 (en) Metalloenzyme inhibitor compounds
RS61558B1 (en) Crystal form of a pde4 inhibitor
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
EP2958964A4 (en) Treatment of frequently touched surfaces to improve hygiene
EP3632467C0 (en) Inhibitors of complement factor h
HK1222339A1 (en) Inhibitors of metallo-ss-lactamase-enzymes --
DK2928477T3 (en) USE OF TELETOMERASE INHIBITOR IMETELSTAT TO TREAT MYELOFIBROSIS
ZA201409181B (en) Treatment of waste water
HK1221645A1 (en) Benzoquinolone inhibitors of vmat2 vmat2
ZA202207530B (en) Use of phenoxypropylamine compounds to treat depression
IL240763B (en) Halogenopyrazoles as inhibitors of therombin
PL2888228T3 (en) Inhibitors of cd40-traf6 interaction
PT3055333T (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
PT3689913T (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
ZA201409002B (en) Treatment of waste water
GB201308117D0 (en) Inhibitor of calcifying disorders
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors